NasdaqHealth CarePharmaceutical PreparationsHOUSTON, TX

Marker Therapeutics, Inc. MRKR

Ask your AI

Estimated market cap $14.51M16.67M shares, shares as of Aug 7, 2026CIK 1094038

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

12.2% of shares · 3 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in Marker Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 14, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Marker Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Dec 23, 2024. Insiders have two business days to file.

Recent insider trades

Steve Elms Director	Dec 23, 2024 Form 4 ↗	Buy	+$35.5K 11,085 sh @ $3.20	-101.4%
NEA Partners 16, L.P. 10% owner	Dec 23, 2024 Form 4 ↗	Buy	+$1.8M 554,250 sh @ $3.20	-101.4%

All MRKR insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

2.04M shares

25 funds report MRKR. Values checked against market prices.

Funds own 24% of shares (Q2 2026)

35 funds hold the stock.

Q3 2026: 12% · 5,560 of ~8,900 funds reported so far

Q2 202526%
Q3 202521%
Q4 202524%
Q1 202623%
Q2 202624%
Q3 2026 (so far)12%

Q3 2026. 4 new, 3 added to, 3 trimmed, 14 exited since Q2 2026.

Top 13F holders
#
1	Blue Owl Capital Holdings LP 13F ↗	554,250	$593.0K	unchanged
2	Vanguard Capital Management LLC 13F ↗	426,169	$456.0K	unchanged
3	Aisling Capital Management LP 13F ↗	325,370	$348.1K	unchanged
4	Renaissance Technologies LLC 13F ↗	267,350	$286.1K	+7.2%
5	Geode Capital Management, LLC 13F ↗	139,816	$149.6K	unchanged
6	Osaic Holdings, Inc. 13F ↗	111,399	$119.2K	-1.1%
7	Vanguard Fiduciary Trust Co 13F ↗	87,269	$93.4K	unchanged
8	Squarepoint Ops LLC 13F ↗	34,485	$36.9K	New
9	State Street Corp 13F ↗	20,948	$22.4K	unchanged
10	Creative Planning 13F ↗	17,312	$18.5K	unchanged

Download CSV Every fund that holds MRKR, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Marker Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Marker Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2023	28	—	1.63M	$1.2M
Q2 2023	28	0	1.82M	$5.7M
Q3 2023	27	-1	1.87M	$8.5M
Q4 2023	25	-2	1.91M	$10.5M
Q1 2024	27	+2	1.92M	$8.3M
Q2 2024	27	0	1.94M	$10.5M
Q3 2024	27	0	1.94M	$5.5M
Q4 2024	32	+5	4.40M	$49.3M
Q1 2025	31	-1	4.02M	$4.9M
Q2 2025	31	0	3.41M	$5.2M
Q3 2025	32	+1	3.46M	$3.1M
Q4 2025	36	+4	4.04M	$6.0M
Q1 2026	35	-1	3.90M	$5.1M
Q2 2026	35	0	3.97M	$5.8M
Q3 2026	25	-10	2.04M	$2.2M

Each point is a quarter-end, from Q1 2023 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (57055L206). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2023) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes1 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials3 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Marker Therapeutics, Inc.
Address: 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE 1.311, HOUSTON, TX 77021
Phone: (713) 400-6400
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: MRKR (Nasdaq)
Former names: TAPIMMUNE INC. (until 2018); TAPIMMUNE INC (until 2017); GENEMAX CORP (until 2007); EDUVERSE COM (until 2002)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.87−$0.03 (−3.33%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.87 · High $1.20Nov 13, 2026

Aug 13, 2026Low $0.87 · High $1.52Nov 13, 2026

Nov 13, 2025Low $0.87 · High $2.19Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.